Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.49 |
| ▸ | CSF1R | P07333 | 4/20 | 0.49 |
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | FLT4 | P35916 | 4/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | KIF5B | P33176 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170739 | 1.00 | KDR (0.52) | KDRBRAFRAF1LCKPDGFRB | |
| SCHEMBL4167628 | 0.95 | LCK (0.57) | KDRBRAFRAF1LCKPDGFRB | |
| SCHEMBL4175668 | 0.85 | LCK (0.56) | KDRBRAFRAF1LCKPDGFRB | |
| SCHEMBL4498768 | 0.84 | PDGFRB (0.65) | KDRPDGFRBCSF1RFLT3FLT4 | |
| SCHEMBL1099033 | 0.83 | PDGFRB (0.62) | KDRBRAFRAF1PDGFRBCSF1R | |
| SCHEMBL4174983 | 0.82 | PDGFRB (0.59) | KDRBRAFRAF1PDGFRBCSF1R | |
| SCHEMBL4163604 | 0.82 | PDGFRB (0.59) | KDRBRAFRAF1PDGFRBCSF1R | |
| SCHEMBL4178263 | 0.82 | PDGFRB (0.61) | KDRBRAFRAF1PDGFRBCSF1R | |
| SCHEMBL4175618 | 0.82 | PDGFRB (0.61) | KDRBRAFRAF1PDGFRBCSF1R | |
| SCHEMBL4167702 | 0.82 | PDGFRB (0.61) | KDRBRAFRAF1PDGFRBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1994023-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099317-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | KDR 2384/4885BRAF 740/4885RAF1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.